Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Andre Damons | Photo Andre Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Director of Pharmacology in the Department of Pharmacology at the UFS, hosted the first IKS Bio-Trade Indaba, which took place between 24 and 25 November on the Bloemfontein Campus of the UFS.

The inaugural international Indigenous Knowledge and Bio-Trade Indaba, hosted by the University of the Free State (UFS) in collaboration with the Technology Innovation Agency (TIA) – an entity of the Department of Science and Innovation (DSI) – is the ideal platform for various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, conservation, innovation, and commercialisation of the IK-based researched products. 

The IKS Bio-Trade Indaba was championed by the university’s African Medicines Innovation and Technology Development Platform (AMITD), which is funded by TIA. AMITD was established to stimulate economic growth by providing science-based solutions and developing technologies that would utilise indigenous knowledge and South African biodiversity to produce high-quality African traditional-medicine-based proprietary products, focusing on priority diseases. AMITD is a national leader in research, development, and formulation research on traditional medicines and has a strong history in IKS research, community collaboration, and participation initiatives, as well as partnerships with industry on herbal medicines.

The indaba, which took place from 24 to 25 November, was a success, opening much-needed dialogue and engagement on the role of IK-based knowledge in research and commercialisation. Going forward, the indaba will be a vital platform to enhance the role of IKS in inclusive development and transformation.

African traditional medicine should be internationally recognised

Prof Motlalepula Matsabisa, Director of Pharmacology in the UFS Department of Pharmacology and AMITD, said he has a special interest in the pharmacology of traditional medicines and that he wants to see more national, continental, and international collaboration so that the dream of making ATM internationally recognised and a global force can be realised. 

“How do we develop new drugs and medicines based on the knowledge we have. We do this without compromising on good all-inclusive science on ATM. We should take the science and put it on the global stage so that all people will begin to respect it,” said Prof Matsabisa. 

According to him, research conducted by AMITD should address national research priorities, community research needs and aspirations to respond to industry research questions and challenges and develop products, intellectual property (IP), as well as commercialisation. “Research needs to have a societal impact and must impact the quality of life of people. We do responsive research that needs to address old diseases, new diseases, neglected diseases, current pandemics, as well as new and re-emerging pandemics.” 

Elevation of IKS profile can no longer be delayed
 
Dr Vuyisile Phehane, Executive: Bio-Economy at the TIA, said the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. TIA acknowledges the rich, largely untapped source of knowledge within communities that has yet to be fully exploited for the economic and social benefit of particularly the underserved regions of the country, and it should be systematically well researched. 

Dr Vuysile Phehane
Dr Phehane, gave a message of support from TIA, saying the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. (Photo: Andre Damons)


“Sectoral support priorities in agriculture, manufacturing, health innovations, and allied health cannot be overlooked, and neither can the various master plans created to support industrial sectors. This thought leadership has a direct bearing on what we are doing here, engaging in dialogue to shape our future, and seeking ways to collaborate and build long-lasting partnerships in the space of IKS. These partnerships not only serve us in the country, but also on the African continent,” said Dr Phehane. 

According to him, TIA played the role of industry builder and sought to increase its efforts to grow and enhance the role of IKS in inclusive development and transformation. The successful commercialisation of all indigenous knowledge-based projects involving the use of indigenous plants requires the capacity to commercially cultivate these plants. 

Dr Phehane said TIA funded AMITD to ensure that the products of promising indigenous knowledge innovations are safe, effective, and of consistently high quality. “This platform seeks to address generations of market failure by bringing IK into the mainstream of commercialisation and truly equitable benefit sharing. Going forward, 20% of our annual MTEF allocation will be channelled towards IK initiatives, which is significant. This is testament to our commitment to IKS.”

The two-day indaba hosted various panel discussions on multiple aspects of IKS research and developments in human and plant health. Among these were discussions on cannabis research to mitigate cancer multidrug resistance, phytoconstituents for the treatment of diabetes, the development of PHELA, a plant-based product as a treatment for COVID-19, natural product-based colon regulator commercialisation, the development of cannabis and other medicinal plants in wound healing and developing hydrogels, as well as the development of IK-based herbal pesticides.

Discussions also focused on new developments in the indigenous health infusion industry, developments in medicine regulations and IK-based clinical trials in South Africa, as well as African medicines research internationalisation. International panellists included Prof Minke Tang (Beijing University of Chinese Medicine), Dr Samuel Obakiro (HOD, Department of Pharmacology, Busitema University, Uganda), and Dr Kofi Donkor (Centre for Plant Medicine Research, Mampong, Ghana), all of whom shared experiences on IKS-related research in their respective countries.

IKS one of the areas targeted for investment and growth 

Dr Glen Taylor, Senior Director: Research Development at the UFS, said the Department of Pharmacology is one of the fastest-growing departments in the Faculty of Health Sciences at the UFS, and attracts a large number of applications from national and international scholars largely due to a very understated Prof Matsabisa.

“We always look at areas where we need to invest in the future and grow, and IKS is one of those areas we targeted and invested in significantly. Through the research and work in IKS, this is done to reposition the institution as a research-led university that is relevant to its communities and societies.” 
The TIA UFS IKS International Indaba was funded by the TIA IKS unit and the Department of Pharmacology – AMITD platform.

News Archive

Eye tracker device a first in Africa
2013-07-31

 

 31 July 2013

Keeping an eye on empowerment

"If we can see what you see, we can think what you think."

Eye-tracking used to be one of those fabulous science-fiction inventions, along with Superman-like bionic ability. Could you really use the movement of your eyes to read people's minds? Or drive your car? Or transfix your enemy with a laser-beam?

Well, actually, yes, you can (apart, perhaps, from the laser beam… ). An eye tracker is not something from science fiction; it actually exists, and is widely used around the world for a number of purposes.

Simply put, an eye tracker is a device for measuring eye positions and eye movement. Its most obvious use is in marketing, to find out what people are looking at (when they see an advertisement, for instance, or when they are wandering along a supermarket aisle). The eye tracker measures where people look first, what attracts their attention, and what they look at the longest. It is used extensively in developed countries to predict consumer behaviour, based on what – literally – catches the eye.

On a more serious level, psychologists, therapists and educators can also use this device for a number of applications, such as analysis and education. And – most excitingly – eye tracking can be used by disabled people to use a computer and thereby operate a number of devices and machines. Impaired or disabled people can use eye tracking to get a whole new lease on life.

In South Africa and other developing countries, however, eye tracking is not widely used. Even though off-the-shelf webcams and open-source software can be obtained extremely cheaply, they are complex to use and the quality cannot be guaranteed. Specialist high-quality eye-tracking devices have to be imported, and they are extremely expensive – or rather – they used to be. Not anymore.

The Department of Computer Science and Informatics (CSI) at the University of the Free State has succeeded in developing a high-quality eye tracker at a fraction of the cost of the imported devices. Along with the hardware, the department has also developed specialised software for a number of applications. These would be useful for graphic designers, marketers, analysts, cognitive psychologists, language specialists, ophthalmologists, radiographers, occupational and speech therapists, and people with disabilities. In the not-too-distant future, even fleet owners and drivers would be able to use this technology.

"The research team at CSI has many years of eye-tracking experience," says team leader Prof Pieter Blignaut, "both with the technical aspect as well as the practical aspect. We also provide a multi-dimensional service to clients that includes the equipment, training and support. We even provide feedback to users.

"We have a basic desktop model available that can be used for research, and can be adapted so that people can interact with a computer. It will be possible in future to design a device that would be able to operate a wheelchair. We are working on a model incorporated into a pair of glasses which will provide gaze analysis for people in their natural surroundings, for instance when driving a vehicle.

"Up till now, the imported models have been too expensive," he continues. "But with our system, the technology is now within reach for anyone who needs it. This could lead to economic expansion and job creation."

The University of the Free State is the first manufacturer of eye-tracking devices in Africa, and Blignaut hopes that the project will contribute to nation-building and empowerment.

"The biggest advantage is that we now have a local manufacturer providing a quality product with local training and support."

In an eye-tracking device, a tiny infra-red light shines on the eye and causes a reflection which is picked up by a high-resolution camera. Every eye movement causes a change in the reflection, which is then mapped. Infra-red light is not harmful to the eye and is not even noticed. Eye movement is then completely natural.

Based on eye movements, a researcher can study cognitive patterns, driver behaviour, attention spans, even thinking patterns. A disabled person could use their eye-movements to interact with a computer, with future technology (still in development) that would enable that computer to control a wheelchair or operate machinery.

The UFS recently initiated the foundation of an eye-tracking interest group for South Africa (ETSA) and sponsor a biennial-eye tracking conference. Their website can be found at www.eyetrackingsa.co.za.

“Eye tracking is an amazing tool for empowerment and development in Africa, “ says Blignaut, “but it is not used as much as it should be, because it is seen as too expensive. We are trying to bring this technology within the reach of anyone and everyone who needs it.”

Issued by: Lacea Loader
Director: Strategic Communication

Telephone: +27 (0) 51 401 2584
Cell: +27 (0) 83 645 2454
E-mail: news@ufs.ac.za
Fax: +27 (0) 51 444 6393

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept